Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery ...Middle East

Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of surgery SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced...

Hence then, the article about phase 2 data for erleada apalutamide plus androgen deprivation therapy following radical prostatectomy in patients with high risk localized prostate cancer show 100 biochemical free recurrence rate more than two years post surgery was published today ( Friday 03/05/2024 - 07:25 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery )

Also on site :

• Thousands rally in Serbia as students continue fight against corruption
• Today’s NYT ‘Strands’ Hints, Spangram and Answers for Sunday, January 18, 2026
• Pardoned Jan 6 rioter chased from pro-ICE rally in Minneapolis after blasting ‘Ice, Ice Baby’ and threats to burn Quran